Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination
TAIPEI and SAN DIEGO, May 5, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced the initiation of a global, multi-center clinical trial. The Company has also submitted an...
GROW Investment Group Secures ipa from ADGM's FSRA, Marking a Key Milestone in Its Middle East Expansion
ABU DHABI, UAE, April 29, 2026 /PRNewswire/ -- GROW Investment Group (GIG), a leading Chinese global asset manager with approximately $1.5 billion in global assets under management, today announced it has received In-Principle Approval (IPA) from...
LFC welcomes PayPal as club's official digital payments partner
LONDON, Nov. 19, 2025 /PRNewswire/ -- Liverpool FC is proud to welcome PayPal as the club's official digital payments partner in a new global, multi-year deal. This marks PayPal's first-ever collaboration with a Premier League club, further...
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines...